Suppr超能文献

建模作为消除巴基斯坦和阿富汗野生脊髓灰质炎病毒传播策略的预防补充免疫活动的见解。

Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.

机构信息

Kid Risk, Inc., Orlando, FL, USA.

出版信息

Risk Anal. 2021 Feb;41(2):266-272. doi: 10.1111/risa.13471. Epub 2020 Mar 6.

Abstract

Many countries use supplemental immunization activities (SIAs) with oral poliovirus vaccine (OPV) to keep their population immunity to transmission high using preventive, planned SIAs (pSIAs) and outbreaks response SIAs (oSIAs). Prior studies suggested that investment in pSIAs saved substantial health and financial costs due to avoided outbreaks. However, questions remain about the benefits of SIAs, particularly with the recent introduction of inactivated poliovirus vaccine (IPV) into routine immunization in all OPV-using countries. The mounting costs of polio eradication activities and the need to respond to oSIAs threatens the use of limited financial resources for pSIAs, including in the remaining countries with endemic transmission of serotype 1 wild poliovirus (WPV1) (i.e., Pakistan and Afghanistan). A recent updated global poliovirus transmission model suggested that the Global Polio Eradication Initiative (GPEI) is not on track to stop transmission of WPV1 in Pakistan and Afghanistan. We use the updated global model to explore the role of pSIAs to achieve WPV1 eradication. We find that unless Pakistan and Afghanistan manage to increase the quality of bivalent OPV (bOPV) pSIAs, which we model as intensity (i.e., sufficiently high-coverage bOPV pSIAs that reach missed children), the model does not lead to successful eradication of WPV1. Achieving WPV1 eradication, the global objectives of the GPEI, and a successful polio endgame depend on effective and sufficient use of OPV. IPV use plays a negligible role in stopping transmission in Pakistan and Afghanistan and most other countries supported by the GPEI, and more IPV use will not help to stop transmission.

摘要

许多国家利用口服脊髓灰质炎疫苗(OPV)补充免疫活动(SIAs),通过预防性、计划性 SIAs(pSIAs)和疫情应对 SIAs(oSIAs)来保持其人群对传播的高免疫力。先前的研究表明,由于避免了疫情,pSIAs 的投资节省了大量的健康和财政成本。然而,关于 SIAs 的益处仍存在疑问,特别是在所有使用 OPV 的国家最近将灭活脊髓灰质炎疫苗(IPV)纳入常规免疫之后。消灭脊灰行动的费用不断增加,以及需要应对 oSIAs,这威胁到有限的财政资源用于 pSIAs,包括在仍有 1 型野生脊髓灰质炎病毒(WPV1)地方性传播的国家(即巴基斯坦和阿富汗)。最近更新的全球脊灰病毒传播模型表明,全球根除脊灰行动倡议(GPEI)未能按计划停止 WPV1 在巴基斯坦和阿富汗的传播。我们使用更新的全球模型来探讨 pSIAs 在实现 WPV1 根除方面的作用。我们发现,除非巴基斯坦和阿富汗设法提高二价 OPV(bOPV)pSIAs 的质量,我们将其建模为强度(即足够高覆盖率的 bOPV pSIAs 能够覆盖到未接种的儿童),否则该模型不会导致 WPV1 的成功根除。实现 WPV1 根除、GPEI 的全球目标以及成功的脊灰终结,取决于有效和充分地使用 OPV。IPV 的使用在巴基斯坦和阿富汗以及 GPEI 支持的大多数其他国家停止传播方面作用微不足道,更多的 IPV 使用无助于阻止传播。

相似文献

2
Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.
Risk Anal. 2019 Feb;39(2):389-401. doi: 10.1111/risa.13194. Epub 2018 Sep 21.
7
Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan.
Risk Anal. 2023 Apr;43(4):660-676. doi: 10.1111/risa.13983. Epub 2022 Jun 23.
8
Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020.
Vaccine. 2021 Oct 8;39(42):6250-6255. doi: 10.1016/j.vaccine.2021.09.020. Epub 2021 Sep 16.

引用本文的文献

3
Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.
Gates Open Res. 2023 Apr 17;7:55. doi: 10.12688/gatesopenres.14511.1. eCollection 2023.
5
Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan.
Risk Anal. 2023 Apr;43(4):660-676. doi: 10.1111/risa.13983. Epub 2022 Jun 23.
6
Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019-2023.
Open Forum Infect Dis. 2021 May 23;8(7):ofab264. doi: 10.1093/ofid/ofab264. eCollection 2021 Jul.
7
The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
Vaccine. 2023 Apr 6;41 Suppl 1:A12-A18. doi: 10.1016/j.vaccine.2021.04.026. Epub 2021 Apr 27.
8
An Updated Economic Analysis of the Global Polio Eradication Initiative.
Risk Anal. 2021 Feb;41(2):393-406. doi: 10.1111/risa.13665.
9
Modeling and Managing Poliovirus Risks: We are Where we are….
Risk Anal. 2021 Feb;41(2):223-228. doi: 10.1111/risa.13668.
10
Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Risk Anal. 2021 Feb;41(2):364-375. doi: 10.1111/risa.13664.

本文引用的文献

1
Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.
Risk Anal. 2021 Feb;41(2):248-265. doi: 10.1111/risa.13447. Epub 2020 Jan 20.
2
Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Expert Rev Vaccines. 2019 Jul;18(7):725-736. doi: 10.1080/14760584.2019.1635463. Epub 2019 Jul 2.
3
Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use.
MDM Policy Pract. 2017 Mar 1;2(1):2381468317697002. doi: 10.1177/2381468317697002. eCollection 2017 Jan-Jun.
4
Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.
Risk Anal. 2019 Feb;39(2):389-401. doi: 10.1111/risa.13194. Epub 2018 Sep 21.
5
Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
Expert Rev Vaccines. 2018 Aug;17(8):739-751. doi: 10.1080/14760584.2018.1506333. Epub 2018 Aug 9.
7
Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.
J Infect Dis. 2017 Jul 1;216(suppl_1):S217-S225. doi: 10.1093/infdis/jix105.
8
Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.
J Vaccines Vaccin. 2016 Oct;7(5). doi: 10.4172/2157-7560.1000340. Epub 2016 Oct 3.
9
Poliovirus vaccination during the endgame: insights from integrated modeling.
Expert Rev Vaccines. 2017 Jun;16(6):577-586. doi: 10.1080/14760584.2017.1322514. Epub 2017 May 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验